CRSP Quote, Financials, Valuation and Earnings

Addex Therapeutics has a net margin of -- compared to CRISPR Therapeutics AG's net margin of -2841.85%. CRISPR Therapeutics AG's return on equity of -- beat Addex Therapeutics's return on equity of 91.08%.

CRISPR Therapeutics AG has a consensus price target of $81.75, signalling upside risk potential of 99.68%. On the other hand Addex Therapeutics has an analysts' consensus of -- which suggests that it could grow by 275.4%. Given that Addex Therapeutics has higher upside potential than CRISPR Therapeutics AG, analysts believe Addex Therapeutics is more attractive than CRISPR Therapeutics AG.

CRISPR Therapeutics AG has a beta of 1.621, which suggesting that the stock is 62.069% more volatile than S&P 500. In comparison Addex Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.

CRISPR Therapeutics AG quarterly revenues are --, which are smaller than Addex Therapeutics quarterly revenues of $62.3K. CRISPR Therapeutics AG's net income of -$85.9M is lower than Addex Therapeutics's net income of -$1.8M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Addex Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 14.76x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Lonza Group has a net margin of -- compared to CRISPR Therapeutics AG's net margin of --. CRISPR Therapeutics AG's return on equity of -- beat Lonza Group's return on equity of 5.75%.

CRISPR Therapeutics AG has a consensus price target of $81.75, signalling upside risk potential of 99.68%. On the other hand Lonza Group has an analysts' consensus of -- which suggests that it could fall by --. Given that CRISPR Therapeutics AG has higher upside potential than Lonza Group, analysts believe CRISPR Therapeutics AG is more attractive than Lonza Group.

CRISPR Therapeutics AG has a beta of 1.621, which suggesting that the stock is 62.069% more volatile than S&P 500. In comparison Lonza Group has a beta of 0.980, suggesting its less volatile than the S&P 500 by 1.968%.

CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lonza Group offers a yield of 0.74% to investors and pays a quarterly dividend of $0.44 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Lonza Group pays out 40.21% of its earnings as a dividend. Lonza Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CRISPR Therapeutics AG quarterly revenues are --, which are smaller than Lonza Group quarterly revenues of --. CRISPR Therapeutics AG's net income of -$85.9M is higher than Lonza Group's net income of --. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Lonza Group's PE ratio is 67.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 5.76x for Lonza Group. Usually stocks with elevated PS ratios are considered overvalued.

NLS Pharmaceutics has a net margin of -- compared to CRISPR Therapeutics AG's net margin of --. CRISPR Therapeutics AG's return on equity of -- beat NLS Pharmaceutics's return on equity of --.

CRISPR Therapeutics AG has a consensus price target of $81.75, signalling upside risk potential of 99.68%. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 12574.27%. Given that NLS Pharmaceutics has higher upside potential than CRISPR Therapeutics AG, analysts believe NLS Pharmaceutics is more attractive than CRISPR Therapeutics AG.

CRISPR Therapeutics AG has a beta of 1.621, which suggesting that the stock is 62.069% more volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend.

CRISPR Therapeutics AG quarterly revenues are --, which are smaller than NLS Pharmaceutics quarterly revenues of --. CRISPR Therapeutics AG's net income of -$85.9M is higher than NLS Pharmaceutics's net income of --. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -- compared to CRISPR Therapeutics AG's net margin of 37.71%. CRISPR Therapeutics AG's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -2.89%.

CRISPR Therapeutics AG has a consensus price target of $81.75, signalling upside risk potential of 99.68%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $493.61 which suggests that it could grow by 20.93%. Given that CRISPR Therapeutics AG has higher upside potential than Vertex Pharmaceuticals, analysts believe CRISPR Therapeutics AG is more attractive than Vertex Pharmaceuticals.

CRISPR Therapeutics AG has a beta of 1.621, which suggesting that the stock is 62.069% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.

CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

CRISPR Therapeutics AG quarterly revenues are --, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. CRISPR Therapeutics AG's net income of -$85.9M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 10.00x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.